The impact of comorbidity upon determinants of outcome in patients with lung cancer

on behalf of the Scottish Lung Cancer Foruma

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Survival from lung cancer remains poor in Scotland, UK. It is believed that comorbidity may play an important role in this. The goal of this study was to determine the value of a novel comorbidity scoring system (SCSS) and to compare it with the already established Charlson Comorbidity Index and the modified Glasgow Prognostic Score (mGPS). We also wished to explore the relationship between comorbidity, mGPS and Performance Status (PS). In addition we investigated a number of standard prognostic markers and demographics. This study aimed to determine which of these factors most accurately predicted survival. Methods: Between 2005 and 2008 all newly diagnosed lung cancer patients coming through the Multi-Disciplinary Teams (MDTs) in four Scottish Centres were included in the study. Patient demographics, World Health Organization/Eastern Cooperative Oncology Group performance status, clinico-pathological features, mGPS, comorbidity and proposed primary treatment modality were recorded. Univariate survival analysis was carried out using Kaplan-Meier method and the log rank test. Results: This large unselected population based cohort study of lung cancer patients has demonstrated that a number of important factors have significant impact in terms of survival. It has gone further by showing that the factors which influence survival are different, depending upon the stage of cancer at diagnosis and the potential treatment strategy. The novel comorbidity scoring system, the SCSS, has compared very favourably with the more established CCI. Conclusion: This study has identified that a variety of factors are independent prognostic determinants of outcome in lung cancer. There appear to be clear differences between the early and late stage groups.

Original languageEnglish
Pages (from-to)186-192
Number of pages7
JournalLung Cancer
Volume87
Issue number2
Early online date29 Nov 2014
DOIs
Publication statusPublished - Feb 2015

Fingerprint

Comorbidity
Lung Neoplasms
Survival
Demography
Scotland
Survival Analysis
Cohort Studies
Therapeutics
Population
Neoplasms

Keywords

  • Comorbidity
  • Epidemiology
  • Lung cancer
  • NSCLC
  • Outcomes
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

The impact of comorbidity upon determinants of outcome in patients with lung cancer. / on behalf of the Scottish Lung Cancer Foruma.

In: Lung Cancer, Vol. 87, No. 2, 02.2015, p. 186-192.

Research output: Contribution to journalArticle

on behalf of the Scottish Lung Cancer Foruma. / The impact of comorbidity upon determinants of outcome in patients with lung cancer. In: Lung Cancer. 2015 ; Vol. 87, No. 2. pp. 186-192.
@article{5ad1e961a3004799a1781a86a5bf744f,
title = "The impact of comorbidity upon determinants of outcome in patients with lung cancer",
abstract = "Background: Survival from lung cancer remains poor in Scotland, UK. It is believed that comorbidity may play an important role in this. The goal of this study was to determine the value of a novel comorbidity scoring system (SCSS) and to compare it with the already established Charlson Comorbidity Index and the modified Glasgow Prognostic Score (mGPS). We also wished to explore the relationship between comorbidity, mGPS and Performance Status (PS). In addition we investigated a number of standard prognostic markers and demographics. This study aimed to determine which of these factors most accurately predicted survival. Methods: Between 2005 and 2008 all newly diagnosed lung cancer patients coming through the Multi-Disciplinary Teams (MDTs) in four Scottish Centres were included in the study. Patient demographics, World Health Organization/Eastern Cooperative Oncology Group performance status, clinico-pathological features, mGPS, comorbidity and proposed primary treatment modality were recorded. Univariate survival analysis was carried out using Kaplan-Meier method and the log rank test. Results: This large unselected population based cohort study of lung cancer patients has demonstrated that a number of important factors have significant impact in terms of survival. It has gone further by showing that the factors which influence survival are different, depending upon the stage of cancer at diagnosis and the potential treatment strategy. The novel comorbidity scoring system, the SCSS, has compared very favourably with the more established CCI. Conclusion: This study has identified that a variety of factors are independent prognostic determinants of outcome in lung cancer. There appear to be clear differences between the early and late stage groups.",
keywords = "Comorbidity, Epidemiology, Lung cancer, NSCLC, Outcomes, Treatment",
author = "Derek Grose and Morrison, {David S.} and Graham Devereux and Richard Jones and Dave Sharma and Colin Selby and Kirsty Docherty and David McIntosh and Marianne Nicolson and McMillan, {Donald C.} and Robert Milroy and {on behalf of the Scottish Lung Cancer Foruma}",
year = "2015",
month = "2",
doi = "10.1016/j.lungcan.2014.11.012",
language = "English",
volume = "87",
pages = "186--192",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - The impact of comorbidity upon determinants of outcome in patients with lung cancer

AU - Grose, Derek

AU - Morrison, David S.

AU - Devereux, Graham

AU - Jones, Richard

AU - Sharma, Dave

AU - Selby, Colin

AU - Docherty, Kirsty

AU - McIntosh, David

AU - Nicolson, Marianne

AU - McMillan, Donald C.

AU - Milroy, Robert

AU - on behalf of the Scottish Lung Cancer Foruma

PY - 2015/2

Y1 - 2015/2

N2 - Background: Survival from lung cancer remains poor in Scotland, UK. It is believed that comorbidity may play an important role in this. The goal of this study was to determine the value of a novel comorbidity scoring system (SCSS) and to compare it with the already established Charlson Comorbidity Index and the modified Glasgow Prognostic Score (mGPS). We also wished to explore the relationship between comorbidity, mGPS and Performance Status (PS). In addition we investigated a number of standard prognostic markers and demographics. This study aimed to determine which of these factors most accurately predicted survival. Methods: Between 2005 and 2008 all newly diagnosed lung cancer patients coming through the Multi-Disciplinary Teams (MDTs) in four Scottish Centres were included in the study. Patient demographics, World Health Organization/Eastern Cooperative Oncology Group performance status, clinico-pathological features, mGPS, comorbidity and proposed primary treatment modality were recorded. Univariate survival analysis was carried out using Kaplan-Meier method and the log rank test. Results: This large unselected population based cohort study of lung cancer patients has demonstrated that a number of important factors have significant impact in terms of survival. It has gone further by showing that the factors which influence survival are different, depending upon the stage of cancer at diagnosis and the potential treatment strategy. The novel comorbidity scoring system, the SCSS, has compared very favourably with the more established CCI. Conclusion: This study has identified that a variety of factors are independent prognostic determinants of outcome in lung cancer. There appear to be clear differences between the early and late stage groups.

AB - Background: Survival from lung cancer remains poor in Scotland, UK. It is believed that comorbidity may play an important role in this. The goal of this study was to determine the value of a novel comorbidity scoring system (SCSS) and to compare it with the already established Charlson Comorbidity Index and the modified Glasgow Prognostic Score (mGPS). We also wished to explore the relationship between comorbidity, mGPS and Performance Status (PS). In addition we investigated a number of standard prognostic markers and demographics. This study aimed to determine which of these factors most accurately predicted survival. Methods: Between 2005 and 2008 all newly diagnosed lung cancer patients coming through the Multi-Disciplinary Teams (MDTs) in four Scottish Centres were included in the study. Patient demographics, World Health Organization/Eastern Cooperative Oncology Group performance status, clinico-pathological features, mGPS, comorbidity and proposed primary treatment modality were recorded. Univariate survival analysis was carried out using Kaplan-Meier method and the log rank test. Results: This large unselected population based cohort study of lung cancer patients has demonstrated that a number of important factors have significant impact in terms of survival. It has gone further by showing that the factors which influence survival are different, depending upon the stage of cancer at diagnosis and the potential treatment strategy. The novel comorbidity scoring system, the SCSS, has compared very favourably with the more established CCI. Conclusion: This study has identified that a variety of factors are independent prognostic determinants of outcome in lung cancer. There appear to be clear differences between the early and late stage groups.

KW - Comorbidity

KW - Epidemiology

KW - Lung cancer

KW - NSCLC

KW - Outcomes

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84922484384&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2014.11.012

DO - 10.1016/j.lungcan.2014.11.012

M3 - Article

C2 - 25498829

AN - SCOPUS:84922484384

VL - 87

SP - 186

EP - 192

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -